Fin Cascade

Prices as of 8 Oct 2026 close · Not investment advice

Gland Pharma Limited

NSE: GLANDPharmaceuticals

Share price

₹3,079.10

-2.27% close of 8 Oct 2026

Market cap ₹49,266 CrP/E 43.0

Business score

How strong the business is, in one number. The parts behind it are in Pro.

67

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹49,266 Cr

P/E ratio

43.0

P/B ratio

4.9

ROCE

15.1%

ROE

10.7%

Dividend yield

0.6%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹3,150.6052-week low ₹1,596.80

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 17.6% over the past year, and 13.4% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 32.7% to 25.8% over the last four years.

Whether it grew faster than its sector

It grew 13.4% a year against a sector median of 13.1% — 0.3 percentage points faster.

Room to re-rate, or risk of de-rating

At 43.0× earnings it costs 1.8× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 37.3×, the 81st percentile of its own range.

Whether growth justifies the valuation

Priced at 5.4 times its growth rate, on earnings growth of 8%.

Profit growthPrice per ₹1 profitPer 1% growth
Gland Pharma Limited — this one8%/yr43.0×₹5.4
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 61 of 130 on returns, 52 of 127 on growth, 40 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 15.1% on capital, ahead of 53% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹4098 crore of cash from the business, spent ₹2030 crore on plant and equipment, and returned ₹1599 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 7 years, about 86 arrived as cash. Its cash comes back faster than it used to: it went from being waiting 168 days for its cash to waiting 145 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 9 checks clear · 78%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue rose 19.5% year over year and net profit rose 47.4%.

Announced 10 Aug 2026 · Consolidated · Unaudited

Revenue

₹1,800 Cr

Revenue vs last year

+19.5%

Revenue vs last quarter

+3.3%

Net profit

₹317 Cr

Profit vs last year

+47.4%

Profit vs last quarter

-13.6%

Net margin

17.6%

EPS

₹19.23

Earnings call transcript · 17 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹49,266 Cr
Prev close
₹3,079.10
52w High
₹3,171
52w Low
₹1,574
Enterprise value
₹47,727 Cr
Beta
0.7
Price CAGR 1y
61.0%
Price CAGR 3y
25.0%
Price CAGR 5y
-4.0%
Price CAGR 10y
—

Ratios

Return on assets
8.2%
PEG ratio
5.5
P/E ratio
43.0
P/B ratio
4.9
EV / EBITDA
31.3
Industry P/E
38.0
ROCE
15.1%
ROCE 5y average
16.2%
ROE
10.7%
Debt / Equity
0.0
Interest coverage
45.4
Dividend yield
0.6%
ROE 3y average
9.0%
ROE last year
11.0%

Annual P&L

Annual revenue
₹6,431 Cr
Annual profit
₹1,027 Cr
Operating margin
25.0%
Net profit margin
16.0%
EBITDA margin
25.3%
Sales growth 3y
21.1%
Sales growth 5y
13.2%
Profit growth 3y
8.0%
Profit growth 5y
1.0%
EPS
₹62.4
Sales growth TTM
18.0%
Profit growth TTM
49.0%
Dividend payout
32.0%

Quarter P&L

Sales latest quarter
₹1,800 Cr
Profit latest quarter
₹317 Cr
YoY quarterly sales growth
19.6%
YoY quarterly profit growth
47.4%
OPM latest quarter
27.2%

Balance Sheet

Book Value
₹647
Face Value
₹1.0
Total debt
₹284 Cr
Total cash
₹3,359 Cr
Borrowings
₹284 Cr
Reserves / Equity
646.3

Cash Flow

Operating cash flow
₹1,031 Cr
Free cash flow
₹538 Cr
FCF yield
1.0%
Net cash flow
₹803 Cr

Shareholding

Promoter holding
51.8%
FII holding
8.7%
DII holding
30.4%
Public holding
9.1%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Gland Pharma3,150.6045.451,9880.63317.047.11,800.319.615.1
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,2091,3731,5451,5371,4021,4061,3841,4251,5061,4871,6951,7431,800
Expenses9151,0491,1891,1791,1371,1091,0241,0771,1381,1731,2601,2301,311
Material Cost588557558530594588
Change in Inventories-103-37-6.5645-5.0234
Purchases of Stock-in-Trade3.100.881.941.502.281.95
Employee Cost373408385424412444
Other Expenses216209234260227243
Operating Profit294324356359264297360348368314435513489
OPM %24242323192126242421262927
Other Income385337425160584458843911161
Exceptional items (within Other Income)000-2400
Interest56510662371284104
Depreciation65811059392949696101106108109111
Profit before tax261290283298218257299288313284362506435
Tax %26333235343632353135282827
Net Profit194194192192144164205187215184261367317
EPS in Rs121212128.739.9312111311162219
Diluted EPS in Rs111311162219

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,6333,4634,4013,6255,6655,6176,4316,725
Expenses1,6782,1612,8902,6004,3324,3484,8014,974
Material Cost1,9722,240
Change in Inventories103-3.42
Purchases of Stock-in-Trade146.60
Employee Cost1,4021,629
Other Expenses856929
Operating Profit9551,3021,5101,0251,3331,2691,6301,751
OPM %3638342824232526
Other Income139135224184170214292296
Exceptional items (within Other Income)0-24
Interest735726423326
Depreciation9599110147345378424434
Profit before tax9931,3351,6191,0551,1331,0631,4651,587
Tax %22252526323430
Net Profit7739971,2127817726991,0271,129
EPS in Rs5061744747426268
Diluted EPS in Rs4262
Dividend Payout %0000434232

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
13%
3 years
21%
TTM
18%

Compounded profit growth

10 years
—
5 years
1%
3 years
8%
TTM
49%

Stock price CAGR

10 years
—
5 years
-4%
3 years
25%
1 year
61%

Return on equity

10 years
—
5 years
11%
3 years
9%
Last year
11%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital16161616161616
Reserves3,6315,8877,1417,9428,7079,13410,341
Borrowings5554372314284
Other Liabilities4355886718141,5151,7081,807
Minority Interest00
Total Liabilities4,0866,4967,8348,77810,61111,17312,449
Fixed Assets9689541,5021,5713,9474,1474,492
CWIP188338191177238151342
Investments001550000
Other Assets2,9295,2045,9867,0306,4266,8757,614
Total Assets4,0866,4967,8348,77810,61111,22512,511

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity7016057913649979151,031
Cash from Investing Activity-761-1,520-9991,211-1,7491,718188
Cash from Financing Activity-71,2383515-799-433-417
Net Cash Flow-67323-1741,590-1,5522,199803
Free Cash Flow530377269141599521538

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days8371998810099107
Inventory Days250312205421278294284
Days Payable829780127129143136
Cash Conversion Cycle251286225382250250255
Working Capital Days161169168242155173145
ROCE %282515141215

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters585858525252525252525252
FIIs4.914.053.596.884.485.046.907.397.907.587.298.74
DIIs222425333535333333333330
Public1514138.468.338.3387.937.637.627.529.06
No. of Shareholders1,61,6271,36,0211,22,3751,22,6651,22,3581,21,0751,13,7881,10,67197,15194,57891,5001,08,266

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +57.7% (₹1,952.80 → ₹3,079.10)Brick size ₹95.51 (fixed)Bricks 19
₹2,000₹2,500₹3,079Dec '25Jul '26
Price moved up one brickPrice moved down one brickLast close ₹3,079.10 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

1,05,08,061inr

2026-03-31

News

News and filings about Gland Pharma Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Uses as raw material

  • APIs, excipients and pharmaceutical packaging materials
  • ertapenem API / penem raw material
  • heparin API / crude heparin (porcine-derived)

Buys from

  • Beardsell Limited · clean-room / cold-room modular panels — List of Customers logo wall (Gland-Pharma-Limited.…

Sells to

  • Breckenridge Pharmaceutical · 7 injectable products marketed/distributed under Breckenridge label in USA
  • Dr Reddy's Laboratories · portfolio of 8 injectable ANDAs for US marketing/distribution; biologics CDMO collaboratio…
  • Sagent Pharmaceuticals · Heparin Sodium Injection USP (development & supply agreement)
  • Sun Pharmaceutical · injectable products / pharmaceutical shipments

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE068V01023

Plants

  • Cenexi Braine-l'Alleud · Braine-l'Alleud, Walloon Brabant, Belgium
  • Cenexi Fontenay-sous-Bois · Fontenay-sous-Bois, Île-de-France, France
  • Cenexi Herouville-Saint-Clair
  • Cenexi Osny · Osny, Île-de-France, France
  • Gland API manufacturing units Visakhapatnam
  • Gland Biotech drug substance facility Genome Valley
  • Gland Dundigal sterile injectable facility
  • Gland Oncology Facility SEZ Visakhapatnam
  • Gland Pashamylaram sterile injectable facility
  • Gland Penems facility

News impact

Big market events that reach Gland Pharma Limited, and how the effect spreads.

Who it hits first

  • Sterile-injectable makers (Gland, Aurobindo, Lupin, Caplin, Shilpa) face new licensing layer
  • Small job-work sterile units face consolidation pressure
  • CDSCO capacity becomes the approval bottleneck

Who may gain

  • Large compliant players gain share as small units exit
  • Testing and validation service firms gain business

Along the supply chain

Downstream

Hospitals pay slightly more for assured-quality injectables.

Upstream

API and vial suppliers see steadier demand from compliant makers.

Where demand moves

Business

Plants undergo central audits; documentation and QA headcount rise; approvals add months to greenfield timelines.

Capital

Money favours large, audit-ready pharma over small sterile job-workers.

How it spreads across sectors

Healthcare

injectable compliance cost rises; consolidation favours leaders

When it plays out

Immediate

Injectable stocks soften on cost headlines.

Medium term

Cleaner industry commands better US/EU pricing power.

Short term

Watch draft rules, timelines and grandfathering clauses.

Who it hits first

  • US-facing Indian generic exporters (DRREDDY, AUROPHARMA, LUPIN, ZYDUSLIFE, GLAND) face a long-dated tariff threat with zero near-term cost
  • Sentiment hit today; Nifty Pharma -1.3%

Who may gain

  • Domestic-focused pharma/hospitals (APOLLOHOSP, MANKIND, ABBOTINDIA) relatively insulated
  • US-based generic manufacturers long-term if reshoring occurs

Along the supply chain

Downstream

US pharmacies/PBMs and patients would bear higher generic costs if the tariff ever takes effect, which is the political friction that makes near-term enactment on essential generics unlikely.

Upstream

Indian API/intermediate suppliers to these formulators see no near-term change; a post-2028 US reshoring push could shift some API demand but also open US-site sourcing.

Where demand moves

Business

No near-term demand change (0% tariff for 2 years). If enacted post-2028, US buyers of Indian generics would face higher landed cost, incentivising reshoring or supplier switching; specialty/injectable makers are harder to displace.

Capital

Near-term risk-off rotation within pharma from high-US-generics names toward domestic-facing pharma and hospitals; the muted, recoverable Sept-2025 precedent limits sustained outflows.

How it spreads across sectors

Healthcare

Domestic hospitals/branded pharma relatively insulated, mild defensive bid

Pharma

US-generic exporters sentiment-negative near-term, neutral medium-term given phasing

When it plays out

Immediate

Sentiment-driven dip in US-exposed generic exporters (Nifty Pharma -1.3%); no earnings impact

Medium term

Neutral through 2026-27 (0% tariff); structural risk only from Aug-2028 (100%) / Aug-2029 (200%) if unmodified — 2 years to reshore or requalify supply

Short term

Wait-and-watch; watch for exemptions/clarifications on essential generics and any reshoring announcements

Who it hits first

  • Beats: HINDCOPPER +137%, GNFC +88%, GE Vernova +98%, Apollo Micro 81% rev, Gland Pharma 52w high
  • Misses: IGL -25%, Afcons Rs 88 cr loss
  • Mixed: Strides Pharma, Tata Steel (covered separately)

Who may gain

  • Capital goods, defence, copper, specialty pharma beat the bar
  • City gas distribution, construction missed

Along the supply chain

Downstream

Mixed

Upstream

Mixed

Where demand moves

Business

Earnings dispersion shows demand strength in capex/defence; weakness in gas distribution and infra execution

Capital

Rotation favors capital goods, defence, specialty pharma

How it spreads across sectors

Capital Goods

GE Vernova T&D positive

Chemicals

GNFC positive

Construction

Afcons miss negative

Defense

Apollo Micro confirms theme

Healthcare

Gland Pharma positive

Metals & Mining

HINDCOPPER positive

Oil, Gas & Consumable Fuels

IGL negative

codex additions

When it plays out

Immediate

Stock-specific moves

Medium term

Capital goods/defence theme reinforced; gas distribution structural pressure persists

Short term

Analyst upgrades on beats; downgrades on misses

Other sectors it reaches

  • {"causal_chain":"GE Vernova T\u0026D beat reinforces grid modernization and transmission capex; higher equipment ordering can flow through to utilities executing renewable evacuation and interstate transmission projects.","direction":"positive","example_tickers":["POWERGRID","NTPC","TATAPOWER"],"magnitude":"medium","notes":"Beneficiaries are indirect and depend on order awards, regulated capex approvals, and execution timelines.","sector":"Power Utilities \u0026 Grid Operators","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Capital goods and T\u0026D strength implies stronger demand for transformers, switchgear, cables, conductors and industrial electrification products.","direction":"positive","example_tickers":["KEI","POLYCAB","CGPOWER"],"magnitude":"medium","notes":"Often reacts as a broader capex basket when T\u0026D earnings surprise positively.","sector":"Electrical Equipment \u0026 Cables","time_horizon":"1_to_4_weeks"}
  • {"causal_chain":"Capex-theme confirmation can spill into railway electrification, signalling, rolling stock and EPC suppliers, even if Afcons-specific execution weakness tempers pure construction sentiment.","direction":"mixed","example_tickers":["RVNL","IRCON","TITAGARH"],"magnitude":"medium","notes":"Order-backed railway names may benefit, while EPC-heavy names could face scrutiny on margins and execution.","sector":"Railways \u0026 Mobility Infrastructure","time_horizon":"1_to_4_weeks"}
  • {"causal_chain":"Stronger capex and defence/capital-goods earnings support credit demand for working capital, project finance and guarantees; Afcons loss raises select asset-quality and execution-risk questions.","direction":"mixed","example_tickers":["SBIN","BANKBARODA","PFC"],"magnitude":"small","notes":"Impact is broad and second-order; lenders benefit from capex momentum but may price higher risk for infra EPC borrowers.","sector":"Banks \u0026 Infrastructure Finance","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Capex strength supports industrial construction, transmission projects and public infrastructure demand; infra execution disappointments may delay near-term volume conversion.","direction":"mixed","example_tickers":["ULTRACEMCO","AMBUJACEM","RAMCOCEM"],"magnitude":"small","notes":"More relevant if capex momentum translates into physical project execution rather than only equipment orders.","sector":"Cement \u0026 Building Materials","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Higher metals, chemicals, pharma and capital-goods activity increases movement of bulk cargo, project cargo, exports and warehousing demand.","direction":"positive","example_tickers":["ADANIPORTS","CONCOR","TCI"],"magnitude":"small","notes":"Ripple is demand-linked and may lag reported earnings by one or two quarters.","sector":"Logistics, Ports \u0026 Industrial Warehousing","time_horizon":"1_to_6_months"}
  • {"causal_chain":"GNFC strength can improve sentiment toward nitrogen chemicals, fertilizers and agri-input names if margins, gas costs or realization trends look favorable across peers.","direction":"positive","example_tickers":["CHAMBLFERT","RCF","GSFC"],"magnitude":"medium","notes":"GNFC is company-specific, so read-through should be checked against subsidy timing, gas costs and product mix.","sector":"Fertilizers \u0026 Agri Inputs","time_horizon":"1_to_4_weeks"}
  • {"causal_chain":"Copper beat and capex strength point to sustained electrification demand across wiring, motors, EV components and industrial automation supply chains.","direction":"positive","example_tickers":["SONACOMS","MOTHERSON","UNOMINDA"],"magnitude":"small","notes":"Transmission from copper/capex to auto ancillaries is indirect but plausible through electrification and component demand.","sector":"Auto Ancillaries \u0026 EV Supply Chain","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Gland Pharma strength and 52-week high can spill into injectables, CDMO and complex generics sentiment; GNFC beat may also support chemical margin recovery narratives.","direction":"positive","example_tickers":["LAURUSLABS","DIVISLAB","SYNGENE"],"magnitude":"medium","notes":"Best read-through is to companies with export formulations, CDMO exposure or specialty manufacturing leverage.","sector":"Pharma CDMO \u0026 Specialty Chemicals","time_horizon":"1_to_4_weeks"}
  • {"causal_chain":"IGL miss and CGD weakness may indicate pressure from gas pricing, volume softness or margin compression; this can ripple to gas-heavy industrial users and urban consumption proxies.","direction":"mixed","example_tickers":["GUJGA","MGL","KAJARIACER"],"magnitude":"small","notes":"CGD peers may face negative read-through, while downstream gas users could benefit only if input costs soften.","sector":"Consumer Gas-Dependent Industries","time_horizon":"1_to_4_weeks"}

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

11 Aug 2026unspecified₹20
14 Aug 2025unspecified₹18
16 Aug 2024unspecified₹20

Splits, bonuses & buybacks

  • daily-prices repair: 7 rows from NSE's archive (replace 2, delete 0, insert 5), 2023-11-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Nov 2023

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.